During a speech given today in Washington, DC, FDA Commissioner Scott Gottlieb, MD, announced the release of the long-awaited Biosimilar Action Plan.
During a speech given today in Washington, DC, FDA Commissioner Scott Gottlieb, MD, announced the release of the long-awaited Biosimilar Action Plan.
The plan, posted simultaneously on the FDA website, is meant to spur biosimilar competition in the US marketplace by addressing 4 key areas:
“While less than 2% of Americans use biologics, they represent 40% of total spending on prescription drugs,” said Gottlieb. “So, enabling a path to competition for biologics from biosimilars is a key to reducing costs and facilitating more innovation.”
Gottlieb explained that the current payment system and reimbursement models in the United States were designed in a single-source world, where there was typically only 1 biologic in a category and there was a lack of therapeutic variety or competition. However, that is not the case anymore, as many of the biologic categories are highly competitive with many products targeting the same disease.
“And so, we need to adopt a different approach to paying for these drugs. An ideal system would reimburse biologics in a competitively bid scheme, where we could take full advantage of the multi-source competition," he said.
Although potential savings from biosimilars have been estimated to be quite high (a RAND study estimated biosimilars could offer a savings of $54 billion from 2017 to 2026), “The real savings has been just a fraction of even the most conservative initial estimates," Gottlieb said. "You don’t have to look far to understand why. While the FDA has approved 11 biosimilars through 2018, only 3 are marketed in the US. Competition is, for the most part, anemic.”
Gottlieb cited litigation for delaying market access of biosimilar products as one of the reasons for the lack of competition, which can come with costs for patients and payers. To analyze the cost of such delays, the FDA recently conducted an analysis of biosimilar competition across all Organization for Economic Co-operation and Development (OECD) markets, the full results of which will be released soon, according to Gottlieb.
However, the initial findings of the study, which assumed that the savings achieved in the United States from biosimilars in terms of price discounts would be on par with what has been seen in other OECD nations, found that if Americans had the opportunity to purchase FDA-approved and marketed biosimilars, they could have saved more than $4.5 billion in 2017. Importantly, these estimated savings does not include savings from biosimilars approved in 2018.
In addition to litigation delaying market access for biosimilars, Gottlieb discussed how rebating schemes, patent thickets, and long-dated contracts have also deterred the entry of approved biosimilars. “We’re not going to play regulatory whack-a-mole with companies trying to unfairly delay or derail the entry of biosimilar competitors,” said Gottlieb.
In another effort to stave off competition from biosimilars, some payers have required step therapy or prior authorization on the reference biologic before patients are able to access a biosimilar. This is a practice that, according to Gottlieb, the FDA sees “no clinical rationale for,” due to the fact that in order for a biosimilar to be approved, the developer must demonstrate that the potential biosimilar has no clinically meaningful differences to the reference product.
Gottlieb also highlighted some key actions the FDA is taking to further spur competition and bring more biosimilars to the market, such as:
Gottlieb said that the FDA looks forward to participating with the FTC to identify ways to deter anticompetitive behavior and that those efforts “will be announced soon.”
In his final remarks, Gottlieb stressed that encouraging the competition of biosimilars in the US marketplace is not a task the FDA can accomplish alone. Achieving the cost savings projected by biosimilars will require actions from both the public and private sector to align reimbursement and formularies to encourage appropriate biosimilar adoption, drawing attention to and taking action against anticompetitive practices, and educating “providers and patients about biosimilars, and why people should have confidence in the safety and effectiveness of these FDA-approved products," he said.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.